SILVER SPRING, Md. — The Food and Drug Administration has given Teligent approval for its third approval this year. The company announced the approval of its generic of Erygel (Erythromycin Topical Gel, 2%) on Friday.
“Teligent now has 19 topical generic pharmaceutical products in the US portfolio, in addition to our four U.S. injectable products,” Teligent president and CEO Jason Grenfell-Gardner said.
The drug is indicated as a topical treatment for acne vulgaris. It had an estimated market size of roughly $17.6 million for the 12 months ended May 2017, according to QuintilesIMS data. The company said it expects to launch its generic in the third quarter of 2017.
July 21, 2017